-
Electronic (PDF)
-
Site License
-
Enterprisewide
Pouchitis - Pipeline Review, Q4 2010
Global Markets Direct, December 2010, Pages: 20
Pouchitis - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Pouchitis Pipeline Review, Q4 2010”, provides an overview of the Pouchitis therapeutic pipeline. This report provides information on the therapeutic development for Pouchitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pouchitis. “Pouchitis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Pouchitis.
- A review of the Pouchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pouchitis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Pouchitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pouchitis pipeline depth and focus of Pouchitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pouchitis Overview
Therapeutics Development
An Overview of Pipeline Products for Pouchitis
Pouchitis Therapeutics under Development by Companies
Companies Involved in Pouchitis Therapeutics Development
Ocera Therapeutics, Inc.
Atlantic Pharmaceuticals, Inc.
AesRx, LLC.
Pouchitis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
